Colchicine in Patients With Acute Coronary Syndrome

Колхицин у пациентов с острым коронарным синдромом
Stephen J. Quinn, John V. Amerena, Jamie John Layland, Ravinay Bhindi, Dion A. Stub, David Tong, Nay Htun, Philip Roberts‐Thomson, Heath S. L. Adams, Andy S.C. Yong, Melanie Freeman, Nicholas John Collins, Laurence Guy Howes, Andrew Wilson, Arthur Nasis, Chin Hiew, Rumes Kanna Sriamareswaran, WILLIAM M. WILSON, William van Gaal, Robert Whitbourn, A. Lee, Chris Hengel, Kaleab Asrress, Andrew Wilson, David C. Tong
2020-08-29

acute coronary syndromeanti-inflammatory therapycolchicinerandomized controlled trialsecondary prevention
Background: Inflammation plays a crucial role in clinical manifestations and complications of acute coronary syndromes (ACS). Colchicine, a commonly used treatment for gout, has recently emerged as a novel therapeutic option in cardiovascular medicine owing to its anti-inflammatory properties. We sought to determine the potential usefulness of colchicine treatment in patients with ACS. Methods: This was a multicenter, randomized, double-blind, placebo-controlled trial involving 17 hospitals in Australia that provide acute cardiac care service. Eligible participants were adults (18–85 years) who presented with ACS and had evidence of coronary artery disease on coronary angiography managed with either percutaneous coronary intervention or medical therapy. Patients were assigned to receive either colchicine (0.5 mg twice daily for the first month, then 0.5 mg daily for 11 months) or placebo, in addition to standard secondary prevention pharmacotherapy, and were followed up for a minimum of 12 months. The primary outcome was a composite of all-cause mortality, ACS, ischemia-driven (unplanned) urgent revascularization, and noncardioembolic ischemic stroke in a time to event analysis. Results: A total of 795 patients were recruited between December 2015 and September 2018 (mean age, 59.8±10.3 years; 21% female), with 396 assigned to the colchicine group and 399 to the placebo group. Over the 12-month follow-up, there were 24 events in the colchicine group compared with 38 events in the placebo group ( P =0.09, log-rank). There was a higher rate of total death (8 versus 1; P =0.017, log-rank) and, in particular, noncardiovascular death in the colchicine group (5 versus 0; P =0.024, log-rank). The rates of reported adverse effects were not different (colchicine 23.0% versus placebo 24.3%), and they were predominantly gastrointestinal symptoms (colchicine, 23.0% versus placebo, 20.8%). Conclusions: The addition of colchicine to standard medical therapy did not significantly affect cardiovascular outcomes at 12 months in patients with ACS and was associated with a higher rate of mortality. Registration: URL: https://www.anzctr.org.au ; Unique identifier: ACTRN12615000861550.
1
Adding colchicine to standard secondary prevention therapy did not significantly improve clinical outcomes in patients with acute coronary syndrome.
2
Colchicine was associated with higher total mortality than placebo during 12 months (8 versus 1 deaths; P=0.017), particularly higher noncardiovascular mortality (5 versus 0; P=0.024).
3
In this multicenter randomized trial of 795 ACS patients, colchicine produced fewer composite cardiovascular events than placebo, but the difference was not statistically significant (24 versus 38; P=0.09).
4
Reported adverse effects were similar between colchicine and placebo groups (23.0% versus 24.3%), with gastrointestinal symptoms predominating.
5
The trial evaluated colchicine at 0.5 mg twice daily for one month followed by 0.5 mg daily for 11 months in adults with ACS and angiographically confirmed coronary artery disease.

Adults with acute coronary syndrome and angiographically confirmed coronary artery disease managed with percutaneous coronary intervention or medical therapy

The efficacy and safety of adjunctive colchicine therapy in reducing recurrent ischemic and mortality outcomes during 12-month follow-up

Publication Details
Publication Date
2020-08-29
Journal
Publisher
ISSN
Cited by
403
Access Type
Author Information
Authors
Stephen J. Quinn
John V. Amerena
Jamie John Layland
Ravinay Bhindi
Dion A. Stub
David Tong
Nay Htun
Philip Roberts‐Thomson
Heath S. L. Adams
Andy S.C. Yong
Melanie Freeman
Nicholas John Collins
Laurence Guy Howes
Andrew Wilson
Arthur Nasis
Chin Hiew
Rumes Kanna Sriamareswaran
WILLIAM M. WILSON
William van Gaal
Robert Whitbourn
A. Lee
Chris Hengel
Kaleab Asrress
Andrew Wilson
David C. Tong
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%